1. Introduction {#sec1-ijerph-15-02622}
===============

Psoriasis and psoriatic arthritis (PsA) are chronic disabling diseases that have a substantial negative impact on a patients' quality of life, resulting in a great physical, emotional, and social burden \[[@B1-ijerph-15-02622]\]. An increasing trend in psoriasis and psoriatic arthritis prevalence has been observed in several countries \[[@B2-ijerph-15-02622],[@B3-ijerph-15-02622],[@B4-ijerph-15-02622],[@B5-ijerph-15-02622],[@B6-ijerph-15-02622],[@B7-ijerph-15-02622]\], making them serious global problems.

Over the past decade there has been greater recognition of increased mortality associated with psoriasis \[[@B7-ijerph-15-02622],[@B8-ijerph-15-02622],[@B9-ijerph-15-02622],[@B10-ijerph-15-02622]\], particularly due to cardiovascular disease \[[@B10-ijerph-15-02622],[@B11-ijerph-15-02622]\]. Mortality studies have been carried out for psoriatic arthritis as well \[[@B8-ijerph-15-02622],[@B10-ijerph-15-02622],[@B12-ijerph-15-02622],[@B13-ijerph-15-02622],[@B14-ijerph-15-02622],[@B15-ijerph-15-02622],[@B16-ijerph-15-02622],[@B17-ijerph-15-02622]\]. Most of the studies have been limited by their small sample size and selection bias in community- or hospital-based studies \[[@B12-ijerph-15-02622],[@B14-ijerph-15-02622],[@B15-ijerph-15-02622],[@B16-ijerph-15-02622],[@B17-ijerph-15-02622],[@B18-ijerph-15-02622]\]. Besides, it is unclear whether disease severity and presence of PsA are associated with mortality risk in psoriasis patients. This study aimed to investigate the mortality risk in psoriasis patients with respect to the psoriasis severity and presence of PsA.

2. Materials and Methods {#sec2-ijerph-15-02622}
========================

2.1. Data Source {#sec2dot1-ijerph-15-02622}
----------------

A cohort study was conducted using data from the National Health Insurance Research Database (NHIRD), which covered over 99.9% of the nearly 23 million people in Taiwan between 2000 and 2012. The NHIRD database contains registration files and original reimbursement claims data, including demographic characteristics, outpatient and inpatient services, diagnostic codes, procedures performed, and details of prescriptions and comorbidities. The NHIRD has been widely used in epidemiological studies \[[@B19-ijerph-15-02622],[@B20-ijerph-15-02622],[@B21-ijerph-15-02622],[@B22-ijerph-15-02622],[@B23-ijerph-15-02622],[@B24-ijerph-15-02622],[@B25-ijerph-15-02622],[@B26-ijerph-15-02622]\]. Previous studies have confirmed the high accuracy and validity of the NHIRD in recording psoriasis \[[@B10-ijerph-15-02622]\]. This study was performed in accordance with the Helsinki Declaration and was approved by the National Health Research Institutes and the Institutional Review Board of Taipei Veterans General Hospital (IRB: 2015-02-011CC).

2.2. Study Population and Study Design {#sec2dot2-ijerph-15-02622}
--------------------------------------

We enrolled patients with a new diagnosis of psoriasis in the NHIRD between 1 January 2000, and 31 December 2001. Subjects with prior psoriasis diagnosis were excluded. The date of the first psoriasis diagnosis was defined as the index date, which was the start of follow-up for these patients. Subjects were considered to have psoriasis only if the diagnosis was made by dermatologists or rheumatologists and the condition occurred in an inpatient setting or required three or more outpatient visits. Psoriasis was identified by International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes 696.0, 696.1, and 696.8. Patients were classified into groups with PsA, which were identified using ICD-9-CM code 696.0 during the same period; otherwise, patients were considered to have psoriasis without PsA (PsO). Psoriasis severity was classified as mild and severe. Severe psoriasis was defined as disease requiring systemic therapy and/or phototherapy. All other cases were classified as mild psoriasis.

2.3. Matched Controls without Psoriasis {#sec2dot3-ijerph-15-02622}
---------------------------------------

For each patient with psoriasis, one matched control without psoriasis were randomly selected from the database within the same observational period. These subjects were matched for age and sex.

2.4. Outcome Measurement {#sec2dot4-ijerph-15-02622}
------------------------

Since the National Health Insurance is a mandatory universal health insurance program open to all Taiwanese residents, withdrawal from the insurance is almost always due to death. All study subjects were followed from the index date to withdrawal from the insurance or 31 December 2012, whichever date came first. Subjects with the condition mentioned were considered censored in the analysis.

2.5. Systemic Treatment {#sec2dot5-ijerph-15-02622}
-----------------------

Systemic treatment was defined as any systemic anti-psoriatic therapy, including methotrexate, azathioprine, cyclosporine, systemic retinoids, mycophenolate mofetil, hydroxyurea, and biologic agents (i.e., etanercept, adalimumab, or ustekinumab).

2.6. Statistical Analysis {#sec2dot6-ijerph-15-02622}
-------------------------

The demographic information of patients was compared by using χ^2^ tests for categorical variables and *t*-tests for continuous variables. Death rates per 1000 patient-years and 95% confidence intervals (CIs) were calculated according to psoriasis status. Cox proportional hazards analysis was used to compare the mortality risks. The model was adjusted for age, sex, socioeconomic status, residence (urban, suburban, or rural), and comorbidities (hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, stroke, connective tissue disease, renal disease, chronic liver disease including cirrhosis and hepatitis, chronic obstructive pulmonary disease, and cancer). A two-sided *p* value of \<0.05 was considered to represent a statistically significant difference. All data processing and statistical analyses were performed with Stata version 12 (Stata Corporation, College Station, TX, USA) and statistical analysis software (SAS) version 9.1 (SAS Institute, Cary, NC, USA).

3. Results {#sec3-ijerph-15-02622}
==========

A total of 106,701 patients with incident psoriasis were identified. Among them, 8795 patients had PsA, and 22,542 patients had severe psoriasis. Baseline characteristics are shown in [Table 1](#ijerph-15-02622-t001){ref-type="table"}. The mean age was similar in patients with psoriasis (mean, standard deviation (SD) = 45.1 (18.7) years) and control subjects (mean (SD) = 45.1 (18.8) years). Compared with matched control subjects, psoriasis patients had a higher prevalence of multiple comorbidities, including hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, stroke, connective tissue disease, renal disease, chronic liver disease, cirrhosis and hepatitis, chronic obstructive pulmonary disease, and cancer.

As shown in [Table 2](#ijerph-15-02622-t002){ref-type="table"}, PsA patients (mean (SD) = 44.5 (16.4) years) were younger on average than PsO patients (mean (SD) = 45.2 (18.9) years). Patients with PsA were more likely to have a comorbidity including dyslipidemia (26.3% vs. 24.7%, *p* \< 0.001), connective tissue disease (20.8% vs. 4.9%, *p* \< 0.001), renal disease (8.1% vs. 7.4%, *p* \< 0.001), and chronic liver disease, cirrhosis and hepatitis (26.5% vs. 21.2%, *p* \< 0.001) and were more like to have received systemic treatment (45% vs. 10.6%, *p* \< 0.001) or phototherapy (23.4% vs. 11.9%, *p* \< 0.001) than those with PsO. On the contrary, the incidence of coronary artery disease (15.3% vs. 14.1%, *p* = 0.003), stroke (10.8% vs. 9.1%, *p* \< 0.001), chronic obstructive pulmonary disease (19.5% vs. 17.3%, *p* \< 0.001), and cancer (7.1% vs. 6.4%, *p* = 0.02) was higher in PsO patients than in PsA patients.

A shown in [Table 3](#ijerph-15-02622-t003){ref-type="table"}, the mean age was similar in patients with mild psoriasis (mean (SD) = 45.1 (19.0) years) and severe psoriasis (mean (SD) = 5.0 (17.6) years). Compared with patients with mild psoriasis, those with severe psoriasis were more likely to have comorbidities of hypertension (36.7% vs. 33.1%, *p* \< 0.001), diabetes mellitus (20.6% vs. 18%, *p* \< 0.001), dyslipidemia (27.3% vs. 24.1%, *p* \< 0.001), connective tissue disease (11.5% vs. 4.8%, *p* \< 0.001), renal disease (9% vs. 7.1%, *p* \< 0.001), chronic liver disease including cirrhosis and hepatitis (25.9% vs. 20.5%, *p* \< 0.001), and cancer (7.8% vs. 6.8%, *p* \< 0.001).

During an average of 5.2 (SD 3.1) years of follow-up, the mortality rate was 15.8 per 1000 person-years in psoriasis patients. Compared with control subjects, psoriasis patients had a significantly higher risk of mortality (incidence rate ratio = 1.46; 95% CI 1.41 to 1.51) after multivariable adjustment (hazard ratio (HR) = 1.41; 95% CI 1.36 to 1.46) ([Table 4](#ijerph-15-02622-t004){ref-type="table"}). Both mild and severe psoriasis and presence and absence of PsA are associated with an increased mortality risk. Patients with PsA did not have a higher mortality risk compared with those with PsO (HR = 1.01; 95% CI 0.93 to 1.10). There was no significant difference in mortality risk between patients with severe psoriasis and those with mild psoriasis (HR = 1.00; 95% CI 0.95 to 1.06).

4. Discussion {#sec4-ijerph-15-02622}
=============

In this nationwide population-based study, we found that psoriasis patients with or without arthritis and with mild or severe psoriasis have a significantly increased risk of mortality compared with the control subjects. Our findings are in agreement with those of prior studies \[[@B8-ijerph-15-02622],[@B10-ijerph-15-02622],[@B27-ijerph-15-02622],[@B28-ijerph-15-02622]\].

In the studies by Wong et al. \[[@B15-ijerph-15-02622]\], Ali et al. \[[@B16-ijerph-15-02622]\], and Mok et al. \[[@B18-ijerph-15-02622]\], PsA patients had a 1.62-fold, a 1.36-fold, and 1.59-fold increased mortality risk, respectively. However, Wilson et al. \[[@B17-ijerph-15-02622]\] and Buckley et al. \[[@B12-ijerph-15-02622]\] did not find a significant increase in mortality in PsA patients compared with the general population. Two recent population-based cohort studies showed conflicting results. Ogdie et al. \[[@B8-ijerph-15-02622]\] found that the death rate in 8706 PsA subjects did not differ from that of the general population, whereas Lee et al. \[[@B10-ijerph-15-02622]\] found increased mortality in 9572 PsA patients.

Several studies investigated the mortality risk in psoriasis patients with respect to disease severity \[[@B8-ijerph-15-02622],[@B10-ijerph-15-02622],[@B11-ijerph-15-02622],[@B26-ijerph-15-02622],[@B27-ijerph-15-02622],[@B28-ijerph-15-02622]\]. Among these studies, four suggested an increased mortality in both patients with mild and severe psoriasis compared with the general population \[[@B8-ijerph-15-02622],[@B10-ijerph-15-02622],[@B27-ijerph-15-02622],[@B28-ijerph-15-02622]\]; one reported a significant higher risk of mortality in patients with severe psoriasis \[[@B11-ijerph-15-02622]\]. Another study identified that severe but not mild psoriasis as associated with an increased risk of death \[[@B29-ijerph-15-02622]\]. Growing evidence suggests a link between psoriasis and other comorbidities. Psoriasis patients are more likely to have malignancy, cardiovascular disease, metabolic syndrome, obesity, and diabetes mellitus, particularly in those with PsA and severe skin disease \[[@B27-ijerph-15-02622],[@B28-ijerph-15-02622],[@B30-ijerph-15-02622],[@B31-ijerph-15-02622],[@B32-ijerph-15-02622]\], which could explain the higher mortality risk observed in psoriasis patients. However, in our study, the psoriasis severity and presence of PsA had no impact on the overall mortality risk in psoriasis patients. The non-significant mortality difference between PsO patients and PsA patients could be explained by higher prevalence of cardiovascular disease and malignancy in PsO patients. Compared with the studies of Ogdie et al. \[[@B8-ijerph-15-02622]\] and Lee et al. \[[@B10-ijerph-15-02622]\] which enrolled only adult patients (age ≥18 years), our study included patients aged under 18 years. Since younger patients are less vulnerable to morbidity and mortality, the inclusion of these patients in our cohort might partially explain the nonsignificant effects of psoriasis severity on mortality risk in psoriasis patients. However, further studies are needed to determine the underlying explanations for our findings.

The strengths of our study include the large sample size, a population-based cohort study design, reliable psoriasis diagnosis made by dermatologists and rheumatologists, and a more comprehensive control of potential confounding factors. However, potential limitations of our study should be considered. First, since the NHIRD data did not include clinical assessments, it is not possible to classify psoriasis severity based on clinical measures such as the Physician Global Assessment and Psoriasis Assessment Severity Index. The use of treatment patterns as a marker for psoriasis severity may introduce misclassification bias. It is possible that some untreated patients with severe psoriasis were misclassified as having mild psoriasis. Nevertheless, previous studies have affirmed the reliability and validity of using these methods for grouping severe psoriasis \[[@B33-ijerph-15-02622],[@B34-ijerph-15-02622],[@B35-ijerph-15-02622],[@B36-ijerph-15-02622]\]. Second, there could be a "healthy user" effect in that patients with severe psoriasis need to be healthy enough to be prescribed the therapies, which would result in an underestimate of mortality risk. Third, instead of confirming death with the death certificate data, we identified death using the subjects' withdrawal from insurance. Withdrawal from insurance could be due to a renunciation of citizenship. However, this method has been validated in a previous study \[[@B37-ijerph-15-02622]\]. Fourth, the information regarding causes of mortality is lacking in our database, therefore, precluding us from further analysis in this study. Finally, the Taiwanese population is predominantly of Chinese descent and caution is needed in extrapolating the results to other ethnic groups.

5. Conclusions {#sec5-ijerph-15-02622}
==============

In summary, our study demonstrated that there was a significantly increased risk of mortality in psoriasis patients. Both mild and severe psoriasis and presence and absence of PsA were associated with an increased mortality risk, whereas the psoriasis severity and presence of PsA had no impact on mortality risk in psoriasis patients. These findings urge physicians to provide comprehensive health assessments and preventive health practices to psoriasis patients even with mild skin disease and no PsA.
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###### 

Baseline characteristics of study sample.

  ------------------------------------------------------------------------------------------------------------------------
  Variables                                         Patients with Psoriasis\   Controls\         *p*             
                                                    (*n =* 106,701)            (*n =* 106,701)                   
  ------------------------------------------------- -------------------------- ----------------- -------- ------ ---------
  Total number of patients with psoriasis           106,701                                                      

  Psoriatic arthritis                               8795                       8.2                               

  Psoriasis with phototherapy                       13,742                     12.9                              

  Psoriasis with systemic therapy                   14,314                     13.4                              

  Psoriasis with phototherapy or systemic therapy   22,542                     21.1                              

  Sex                                                                                                            

   Male                                             62,766                     58.8              62,766   58.8   1.00

   Female                                           43,935                     41.2              43,935   41.2   

  Socioeconomic status                                                                                           

   Low                                              55,814                     52.3              53,027   49.7   \<0.001

   Medium                                           31,281                     29.3              32,003   30     

   High                                             19,606                     18.4              21,671   20.3   

  Residence                                                                                                      

   Urban                                            62,902                     59                65,208   61.1   \<0.001

   Suburban                                         34,364                     32.2              31,968   30     

   Rural                                            9435                       8.8               9525     8.9    

  Comorbidity                                                                                                    

   Hypertension                                     36,156                     33.9              23,916   22.4   \<0.001

   Diabetes mellitus                                19,769                     18.5              9822     9.2    \<0.001

   Dyslipidemia                                     26,474                     24.6              15,706   14.7   \<0.001

   Coronary artery disease                          16,224                     15.2              9379     8.8    \<0.001

   Stroke                                           11,412                     10.7              7043     6.6    \<0.001

   Connective tissue disease                        6599                       6.2               2220     2.1    \<0.001

   Renal disease                                    7993                       7.5               4044     3.8    \<0.001

   Chronic liver disease, cirrhosis and hepatitis   23,107                     21.7              14,143   13.3   \<0.001

   Chronic obstructive pulmonary disease            20,599                     19.3              13,648   12.8   \<0.001

   Cancer                                           7511                       7                 5384     5.1    \<0.001
  ------------------------------------------------------------------------------------------------------------------------
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###### 

Characteristics of psoriatic patients according to existence of arthritis.

  Variables                                           Psoriatic Patients   *p*                  
  --------------------------------------------------- -------------------- ------ ------ ------ ---------
  Total number of patients                            97,906               91.8   8795   8.2    
  Sex                                                                                           
   Male                                               57,532               58.8   5234   59.5   0.17
   Female                                             40,374               41.2   3561   40.5   
  Comorbidity                                                                                   
   Hypertension                                       33,140               33.9   3016   34.3   0.40
   Diabetes mellitus                                  18,158               18.6   1611   18.3   0.60
   Dyslipidemia                                       24,161               24.7   2313   26.3   \<0.001
   Coronary artery disease                            14,982               15.3   1242   14.1   0.003
   Stroke                                             10,616               10.8   796    9.1    \<0.001
   Connective tissue disease                          4771                 4.9    1828   20.8   \<0.001
   Renal disease                                      7285                 7.4    708    8.1    0.04
   Chronic liver diseases, cirrhosis, and hepatitis   20,776               21.2   2331   26.5   \<0.001
   Chronic obstructive pulmonary disease              19,080               19.5   1519   17.3   \<0.001
   Cancer                                             6947                 7.1    564    6.4    0.02
  Received phototherapy                               11,684               11.9   2058   23.4   \<0.001
  Received systemic treatment                         10,359               10.6   3955   45     \<0.001
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###### 

Characteristics of psoriatic patients according to disease severity.

  Variables                                           Psoriatic patients   *p*                    
  --------------------------------------------------- -------------------- ------ -------- ------ ---------
  Total number of patients                            84,159               78.9   22,542   21.1   
  Sex                                                                                             
   Male                                               47,978               57     14,788   65.6   \<0.001
   Female                                             36,181               43     7754     34.4   
  Comorbidity                                                                                     
   Hypertension                                       27,873               33.1   8283     36.7   \<0.001
   Diabetes mellitus                                  15,134               18     4635     20.6   \<0.001
   Dyslipidemia                                       20,315               24.1   6159     27.3   \<0.001
   Coronary artery disease                            12,675               15.1   3549     15.7   0.01
   Stroke                                             9103                 10.8   2309     10.2   0.01
   Connective tissue disease                          4000                 4.8    2599     11.5   \<0.001
   Renal disease                                      5970                 7.1    2023     9      \<0.001
   Chronic liver diseases, cirrhosis, and hepatitis   17,274               20.5   5833     25.9   \<0.001
   Chronic obstructive pulmonary disease              16,289               19.4   4310     19.1   0.43
   Cancer                                             5749                 6.8    1762     7.8    \<0.001
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###### 

Risk of mortality in psoriatic patients.

                                         Number of Participants   Number of Deaths   Number of Deaths per 1000 Person-Years   Incidence Rate Ratio (95% CI)   Age- and Sex-Adjusted HR (95% CI)   Multivariable-Adjusted HR \* (95% CI)
  -------------------------------------- ------------------------ ------------------ ---------------------------------------- ------------------------------- ----------------------------------- ---------------------------------------
  Control                                106,701                  5998               10.8                                     1                               1                                   1
  Total number of psoriatic patients     106,701                  8626               15.8                                     1.46 (1.41--1.51)               1.48 (1.44--1.53)                   1.41 (1.36--1.46)
  Psoriatic patients without arthritis   97,906                   8053               16                                       1.49 (1.44--1.54)               1.48 (1.43--1.53)                   1.41 (1.36--1.46)
  Psoriatic patients with arthritis      8795                     573                12.6                                     1.17 (1.07--1.27)               1.56 (1.43--1.70)                   1.52 (1.39--1.66)
  Mild psoriatic patients                84,159                   6780               16.1                                     1.50 (1.44--1.55)               1.48 (1.43--1.53)                   1.41 (1.36--1.46)
  Severe psoriatic patients              22,542                   1846               14.5                                     1.34 (1.27--1.41)               1.51 (1.43--1.59)                   1.43 (1.35--1.51)
  Psoriatic patients without arthritis   97,906                   8053               16                                       1                               1                                   1
  Psoriatic patients with arthritis      8795                     573                12.6                                     0.79 (0.72--0.86)               0.99 (0.91--1.08)                   1.01 (0.93--1.10)
  Mild psoriatic patients                84,159                   6780               16.1                                     1                               1                                   1
  Severe psoriatic patients              22,542                   1846               14.5                                     0.90 (0.85--0.95)               0.99 (0.94--1.05)                   1.00 (0.95--1.06)

\* Adjusted for age, sex, socioeconomic status, residence, hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, stroke, connective tissue disease, renal diseases, chronic liver diseases and cirrhosis and hepatitis, chronic obstructive pulmonary disease, and cancer. CI, confidence interval; HR, hazard ratio.
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